请输入搜索关键词,或者关键词不小于两个字符!
包含特殊字符,请重新输入
您的搜索词太长,查询请限制在30个字以内
首页 > 国际会议 > 医学/医疗/医药 > 2020年美国国家癌症综合网络年会

2020年美国国家癌症综合网络年会

National Comprehensive Cancer Network Annual Conference(NCCN 2020)

  • 会议时间: 2020年3月20日-22日
  • 会议类型: 医疗
  • 所在国家: 北美洲 - 美国 - 奥兰多
  • 主办单位: NCCN
会议简介

庆祝NCCN成立25周年,并探索新的会议产品和选项!今年的议程将包括30次教育会议,这些会议将介绍肿瘤学护理的最新进展,包括互动式患者案例研究。请继续关注完整的会议议程。

加入来自美国和全球各地的1,650多位注册人,其中包括肿瘤学家(社区和学术机构),肿瘤学研究员,护士,药剂师以及其他参与癌症患者护理的卫生保健专业人员。尊敬的意见领袖展示最新的癌症治疗方法,并提供对肿瘤选择NCCN临床实践指南,基于此,NCCN指南中的数据®肿瘤学的基础和质量的举措。话题每年都在变化,但重点是主要的癌症和支持性护理领域。

目标听众

此教育计划旨在满足管理癌症患者的医师/肿瘤科医生,护士,护士,医师助理,药剂师和其他医疗保健专业人员的教育需求。

资质认证

本次会议(NCCN肿瘤学卓越和领导力学院除外)已获得AMA PRA 1类Credit ™和医师的ABIM,ABPath和ABMS MOC积分,并获得护士,药剂师,肿瘤学的积分认证注册商,案件经理和其他肿瘤学专业人士。

官网:www.nccn.org/professionals/meetings/annual_conference.aspx

会议主题
详细介绍

General Session Learning Objectives


Following this program, participants should be able to: 


Challenging Case Review: Breast Cancer

Identify clinical challenges in managing patients with a variety of cancers.

Develop an evidence-based approach for the management of these patients.


Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers

Describe to relevant stakeholders the risks of the human papilloma virus (HPV) to men and women.

Discuss the benefits of vaccination in preventing cancers caused by HPV.

Incorporate appropriate screening and treatment strategies into the management of those at risk for developing HPV-associated cancers.


Optimizing the Management of Endometrial Cancer

Describe how molecular profiling can be used to classify endometrial cancers, assess risk, and guide treatment decisions.

Examine findings from recent trials when making decisions regarding adjuvant treatment for early stage endometrial cancers.

Apply updated recommendations in the NCCN Guidelines® for Uterine Neoplasms when caring for patients with endometrial cancer.


Best Practices for Incorporating Patient-Reported Outcomes into Oncology Care

Discuss the benefits and challenges associated with collecting and utilizing patient-reported outcomes.

Apply best practices for incorporating patient-reported outcomes into routine clinical care.


Selection of Optimal First-Line and Maintenance Therapies in Advanced Ovarian Cancer

Describe workup for selecting candidates for neoadjuvant therapy and HIPEC, and for determining when to perform interval debulking surgery.

Compare and contrast patient- and case-specific features when selecting among the recommended chemotherapy regimens for primary treatment.

Review when to perform BRCA1/2 mutation testing and how to select patients eligible for maintenance olaparib or maintenance bevacizumab.


Cardiovascular Health and Risk Management in Cancer Survivors

Recognize risk factors for the development of cardiovascular disease in cancer survivors.

Review approaches used to screen cancer survivors for cardiovascular disease.

Explain ways to help cancer survivors manage their cardiovascular risk.


Implementing Clinical Trials in the Community Setting

Define the benefits and challenges of implementing trials at community centers.

Review practical steps and resources needed for implementing clinical trials at a community center.


Locoregional Management of Early-Stage Breast Cancer

Outline recommendations for axillary evaluation in patients with early stage breast cancer.

Develop evidence-based strategy for the management of the axilla in patients after pathological complete response to neoadjuvant therapy.

Individualize radiation therapy recommendations based on patient and tumor characteristics.


Key Considerations in Adopting a Value-Based Payment Model

Identify the factors that a collective group of academic cancer centers considers most important when negotiating value-based payment models with payers.

Compare and contrast these factors when defining individual organizational value.


Alternate Sites of Care: Navigating the Changing Reimbursement Environment

Recognize the importance of considering alternate sites of care in today’s healthcare market.

Describe how to safely transition the administration of specific treatment regimens from the inpatient space to the ambulatory setting and eventually into the home.

Discuss strategies to navigate a changing reimbursement environment and changing patient care paradigms.


Management of Metastatic Breast Cancer

Select evidence-based first-line and subsequent-line treatment options for patients with metastatic breast cancer based on hormone- and HER2- receptor status.

Evaluate the available data to determine which biomarkers should be tested to guide therapeutic decisions in patients with metastatic breast cancer.

Review safety profile of targeted agents used in metastatic breast cancer and outline strategies to optimally manage common toxicities.


Role of Biomarkers in Individualizing Treatment Selection for Patients with Cancer

Describe conditions in which Next Generation Sequencing (NGS) would be an appropriate testing technology.

Outline barriers to adoption of broad molecular profiling for all cancer patients.

Describe technical limitations of NGS in selection of immunotherapies.


Role of Biosimilars in the Oncology Ecosystem

Describe the role of biosimilars in the oncology ecosystem and cost reductions resulting from their use.

Identify the challenges of implementing biosimilars in a clinical setting, including concerns about safety and efficacy.


Importance of Primary Care Physician Involvement in Cancer Care

Describe the current role of primary care physicians (PCPs) in cancer care.

Explain the importance of having PCPs as part of the oncology care team.

Identify ways to increase PCP involvement in cancer care.


Challenging Case Review: Lung Cancer

Identify clinical challenges in managing patients with a variety of cancers.

Develop an evidence-based approach for the management of these patients.


NCCN Roundtable Discussion: Emerging Issues in Oncology – Cancer Care in an Election Year

Explain the potential impact of different health care proposals on health care policy and oncology care delivery.

Identify the top policy decisions that could most affect insurance coverage and outcomes for patients with cancer.


Management of Gliomas: Individualized Treatment Options

Recognize the prognostic relevance of 1p/19q co-deletion in patients with anaplastic oligodendroglioma and associated treatment options.

Compare and contrast the recommended treatment options for glioblastoma, based on a patient’s performance status, age, and MGMT promoter methylation status.

Review the evidence supporting procarbazine/lomustine/vincristine and temozolomide as part of adjuvant treatment options for patients with low-grade and anaplastic glioma.


Optimizing Treatment for Head and Neck Cancers

Describe deintensification strategies under investigation for HPV-associated locally advanced oropharyngeal cancer.

Compare and contrast recommended treatment options for both locally advanced and recurrent/metastatic nasopharyngeal cancer.

Identify immunotherapy options for patients with recurrent or metastatic head and neck squamous cell carcinoma.


Evidence-Based Approaches to Smoking Cessation in Patients with Cancer

Recognize how smoking impacts cancer treatment and patient outcomes.

Discuss the key elements of a smoking cessation treatment plan, including pharmacotherapy and behavior therapy.

Apply the NCCN Guidelines® to assess and document patient smoking history and recommend appropriate cessation treatment.


Sequencing Therapy for Patients with Lung Cancer

Identify appropriate treatment for eligible patients with metastatic NSCLC and certain biomarkers, including preferred treatment and sequencing of therapy.

Describe appropriate treatment for eligible patients with metastatic NSCLC who do not have biomarkers, including preferred treatment, sequencing of therapy, and management of adverse events.

Discuss appropriate treatment for eligible patients with small cell lung cancer, including preferred treatment and sequencing of therapy.


A New Frontier in Multimodal Therapy:

Combining Immunotherapy with Radiation, Chemotherapy, or Targeted Agents

Describe the different types of multimodal therapy being employed with immune checkpoint inhibitors in patients with lung cancer.

Discuss the data on the benefits and risks of combining immunotherapy with systemic agents or radiotherapy.

Apply the recommendations in the NCCN Guidelines® for Non-Small Cell Lung Cancer for combining immune checkpoint inhibitors with cytotoxic chemotherapy and targeted agents.


Debate – What is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia:

Chemoimmunotherapy or Small Molecule Inhibitor Therapy?

Review the evidence from recent clinical trials supporting the use of targeted therapy for patients with newly diagnosed CLL.

Recognize the emerging role of IGHV mutation status in the selection of first-line therapy and identify patients with newly diagnosed CLL who could be candidates for chemoimmunotherapy.

Develop an individualized treatment plan for patients with newly diagnosed CLL based on the disease-specific and patient-specific characteristics.


Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Evaluate novel and emerging treatment strategies for acute myeloid leukemia (AML).

Discuss unique supportive care considerations associated with novel and emerging AML therapies.

Describe the current challenges with incorporating novel therapeutic advances in AML management.


Challenging Case Review: Colorectal Cancer

Identify clinical challenges in managing patients with a variety of cancers.

Develop an evidence-based approach for the management of these patients.


Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and 

Management of Hereditary Cancers

Recognize the utility and difficulties associated with multi-gene testing.

Discuss the emerging role of moderate penetrance genes in defining risks for hereditary cancer.

Describe controversies associated with direct-to-consumer genetic testing services.


Advances in the Management of Pancreatic Adenocarcinoma

Identify recent advances in treatment of pancreatic cancer.

Review the recent changes in recommendations for treatment of pancreatic cancer.

Compare and contrast the evidence, risks, and benefits for use of new systemic treatments of pancreatic cancer.


Trimodal Therapy Approaches for Localized Rectal Cancer

Describe current trimodal therapy approaches for treatment of localized rectal cancer.

Evaluate new and emerging data on total neoadjuvant therapy approaches, short-course radiation, and watch-and-wait strategies.

Apply clinical trial data into treatment strategies for localized rectal cancer and identify appropriate patients for these methods.


Emerging Treatment Options for the Management of Metastatic Colorectal Cancer

Review criteria for treatment selection in patients with metastatic colorectal cancer, including interpretation of results from biomarker testing.

Explain results of recent clinical trials of systemic therapies for patients with metastatic colorectal cancer.

Evaluate emerging treatment options and approaches that may improve outcomes in patients with metastatic colorectal cancer.


Multidisciplinary Management of Advanced Kidney Cancer

Recognize the role of multidisciplinary management for treating metastatic renal cell carcinoma (RCC).

Compare and contrast current treatment options for patients with metastatic RCC.

Review the key patient and clinical factors that influence initial treatment selection for patients with metastatic RCC.


Current Topics in Management of Non-Muscle Invasive Bladder Cancer

Review current treatment recommendations for non–muscle invasive bladder cancer.

List implications of the bacillus Calmette Guérin (BCG) shortage, including identification of strategies to help alleviate problems associated with this shortage.

Describe the results of recent clinical trials for non–muscle invasive bladder cancer and their potential impact on treatment.


Recent Developments in the Management of Prostate Cancer

Integrate recent updates to the recommendations in the NCCN Guidelines® for Prostate Cancer into clinical practice.

Determine whether patients with localized prostate cancer are eligible for active surveillance.

Apply the results of recent clinical trials in the non-metastatic castration-resistant prostate cancer setting.

服务项目

1. 会议注册
2. 大会投稿
3. 会员申请
4. 代办签证
5. 预定酒店
6. 预定机票
7. 地接服务
8. 境外游览
9. 商务出行

以上服务请根据您的需求进行选择,关于服务费用或其它问题请点击咨询在线客服。

'
 
提交成功!
'